SPOTLIGHT: Mining companies fund trial

A group of mining companies has agreed to provide $6 million to Australia's Virax to funds tests of its HIV therapy, VIR201. The innovative funding program was inspired by the companies' problems wrestling with the AIDS epidemic that afflicts miners in South Africa. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.